Full Press Release Details
BridgeBio Pharma Secures Up To $1.25 Billion Of Capital From Blue Owl And CPP Investments To Accelerate Commercial Launch.
BBIO
BridgeBio Pharma Secures Up To $1.25 Billion Of Capital From Blue Owl And CPP Investments To Accelerate Commercial Launch
Key Takeaway: BridgeBio Pharma Secures Up To $1.25 Billion Of Capital From Blue Owl And CPP Investments To Accelerate Commercial Launch
Price reaction · baseline $36.91 (2024-01-17 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close
+1.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis